The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
The global Kidney Fibrosis Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Fibrosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Fibrosis Treatment.
Report Scope
The Kidney Fibrosis Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Fibrosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Fibrosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Merck and Co(US)
- Pfizer Inc(US)
- F. Hoffman-La Roche(Switzerland)
- InterMune Inc(US)
- Galectin Therapeutics(US)
- La Jolla Pharmaceutical Company(US)
- ProMetic Life-Sciences Inc(Canada)
- BioLine Rx(Israel)
- Genzyme Corporation(US)
Segment by Type
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Pirfenidone
- Renin Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Vasopeptidase Inhibitors
Segment by Application
- Chronic Kidney Diseases
- Kidney Cancer Treatment
- Others
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Fibrosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Fibrosis Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors
1.2.3 Pirfenidone
1.2.4 Renin Inhibitors
1.2.5 Angiotensin II Receptor Blockers (ARBs)
1.2.6 Vasopeptidase Inhibitors
1.3 Market by Application
1.3.1 Global Kidney Fibrosis Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Chronic Kidney Diseases
1.3.3 Kidney Cancer Treatment
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Fibrosis Treatment Market Perspective (2019-2030)
2.2 Kidney Fibrosis Treatment Growth Trends by Region
2.2.1 Global Kidney Fibrosis Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Kidney Fibrosis Treatment Historic Market Size by Region (2019-2024)
2.2.3 Kidney Fibrosis Treatment Forecasted Market Size by Region (2025-2030)
2.3 Kidney Fibrosis Treatment Market Dynamics
2.3.1 Kidney Fibrosis Treatment Industry Trends
2.3.2 Kidney Fibrosis Treatment Market Drivers
2.3.3 Kidney Fibrosis Treatment Market Challenges
2.3.4 Kidney Fibrosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Fibrosis Treatment Players by Revenue
3.1.1 Global Top Kidney Fibrosis Treatment Players by Revenue (2019-2024)
3.1.2 Global Kidney Fibrosis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Kidney Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kidney Fibrosis Treatment Revenue
3.4 Global Kidney Fibrosis Treatment Market Concentration Ratio
3.4.1 Global Kidney Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Fibrosis Treatment Revenue in 2023
3.5 Kidney Fibrosis Treatment Key Players Head office and Area Served
3.6 Key Players Kidney Fibrosis Treatment Product Solution and Service
3.7 Date of Enter into Kidney Fibrosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Fibrosis Treatment Breakdown Data by Type
4.1 Global Kidney Fibrosis Treatment Historic Market Size by Type (2019-2024)
4.2 Global Kidney Fibrosis Treatment Forecasted Market Size by Type (2025-2030)
5 Kidney Fibrosis Treatment Breakdown Data by Application
5.1 Global Kidney Fibrosis Treatment Historic Market Size by Application (2019-2024)
5.2 Global Kidney Fibrosis Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Kidney Fibrosis Treatment Market Size (2019-2030)
6.2 North America Kidney Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Kidney Fibrosis Treatment Market Size by Country (2019-2024)
6.4 North America Kidney Fibrosis Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Fibrosis Treatment Market Size (2019-2030)
7.2 Europe Kidney Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Kidney Fibrosis Treatment Market Size by Country (2019-2024)
7.4 Europe Kidney Fibrosis Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Fibrosis Treatment Market Size (2019-2030)
8.2 Asia-Pacific Kidney Fibrosis Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Kidney Fibrosis Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Kidney Fibrosis Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Fibrosis Treatment Market Size (2019-2030)
9.2 Latin America Kidney Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Kidney Fibrosis Treatment Market Size by Country (2019-2024)
9.4 Latin America Kidney Fibrosis Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Fibrosis Treatment Market Size (2019-2030)
10.2 Middle East & Africa Kidney Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Kidney Fibrosis Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Kidney Fibrosis Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck and Co(US)
11.1.1 Merck and Co(US) Company Detail
11.1.2 Merck and Co(US) Business Overview
11.1.3 Merck and Co(US) Kidney Fibrosis Treatment Introduction
11.1.4 Merck and Co(US) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.1.5 Merck and Co(US) Recent Development
11.2 Pfizer Inc(US)
11.2.1 Pfizer Inc(US) Company Detail
11.2.2 Pfizer Inc(US) Business Overview
11.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Introduction
11.2.4 Pfizer Inc(US) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.2.5 Pfizer Inc(US) Recent Development
11.3 F. Hoffman-La Roche(Switzerland)
11.3.1 F. Hoffman-La Roche(Switzerland) Company Detail
11.3.2 F. Hoffman-La Roche(Switzerland) Business Overview
11.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Introduction
11.3.4 F. Hoffman-La Roche(Switzerland) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.3.5 F. Hoffman-La Roche(Switzerland) Recent Development
11.4 InterMune Inc(US)
11.4.1 InterMune Inc(US) Company Detail
11.4.2 InterMune Inc(US) Business Overview
11.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Introduction
11.4.4 InterMune Inc(US) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.4.5 InterMune Inc(US) Recent Development
11.5 Galectin Therapeutics(US)
11.5.1 Galectin Therapeutics(US) Company Detail
11.5.2 Galectin Therapeutics(US) Business Overview
11.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Introduction
11.5.4 Galectin Therapeutics(US) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.5.5 Galectin Therapeutics(US) Recent Development
11.6 La Jolla Pharmaceutical Company(US)
11.6.1 La Jolla Pharmaceutical Company(US) Company Detail
11.6.2 La Jolla Pharmaceutical Company(US) Business Overview
11.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Introduction
11.6.4 La Jolla Pharmaceutical Company(US) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.6.5 La Jolla Pharmaceutical Company(US) Recent Development
11.7 ProMetic Life-Sciences Inc(Canada)
11.7.1 ProMetic Life-Sciences Inc(Canada) Company Detail
11.7.2 ProMetic Life-Sciences Inc(Canada) Business Overview
11.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Introduction
11.7.4 ProMetic Life-Sciences Inc(Canada) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.7.5 ProMetic Life-Sciences Inc(Canada) Recent Development
11.8 BioLine Rx(Israel)
11.8.1 BioLine Rx(Israel) Company Detail
11.8.2 BioLine Rx(Israel) Business Overview
11.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Introduction
11.8.4 BioLine Rx(Israel) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.8.5 BioLine Rx(Israel) Recent Development
11.9 Genzyme Corporation(US)
11.9.1 Genzyme Corporation(US) Company Detail
11.9.2 Genzyme Corporation(US) Business Overview
11.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Introduction
11.9.4 Genzyme Corporation(US) Revenue in Kidney Fibrosis Treatment Business (2019-2024)
11.9.5 Genzyme Corporation(US) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
